MedTrace Logo

Retrospective Study on MR Imaging of ET and PD Patients Subjected With MRgFUS Thalamotomy

NCT04570046 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2024-05-01

No results posted yet for this study

Summary

The technological advance of magnetic resonance-guided focused ultrasound (MRgFUS) has once again brought lesion therapy back to the clinical frontline for the treatment of movement disorder. Thus far, the safety of MRgFUS has been widely proven and has just been made available in China in late 2020. We attempted to analyze the neuroplasticity characteristics and altered neural circuit activity in patients subjected with MRgFUS thalamotomy via post-hoc retrospective analysis of archived MR imaging in our site, and to explore potential biomarkers that could be used to predict the treatment outcome.

Conditions

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Xin Lou, MD/PhD · Chinese PLA General Hospital

  • LongSheng Pan, MD/PhD · Chinese PLA General Hospital

Eligibility

Min Age
22 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-18
Primary Completion
2020-08-20
Completion
2020-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04570046 on ClinicalTrials.gov